Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort—the DIABET-IC study
Authors' conclusion
In this contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics, the prevalence and incidence of HF were high, comorbidities were frequent, and the use of antidiabetic agents with cardiovascular benefit was low. Outpatient care seems to be a unique opportunity for a comprehensive T2D approach that encompasses HF prevention, diagnosis, and treatment.
Study context
- Population
- Patients with T2D attending cardiology and endocrinology outpatient clinics in 30 centres in Spain, 2018–2019; 67.6 ± 10.1 years, 31.7% female
- Participants
- 1,249 patients
- Outcome
- Prevalence of HF at baseline and incidence of HF
- Follow-up
- 3 year
Methodological detailsobservational, multicentre, nationwide
- Observational
- Multicentre
- Nationwide
Main finding
As reported in the abstract
Heart failure (HF) at baseline (prevalence)
490 participants
39.2%
Preserved ejection fraction among baseline HF
150
30.6%
New HF diagnoses among those without baseline HF (incidence)
58
7.6%
Incidence rate
3.0 per 100 person-years
Observational data: associations, not effects.
Further findings
Characteristics of HF patients
- Adverse social determinants and chronic conditions (CKD, atherosclerotic CVD) more frequent in HF patients
Independent predictors of incident HF
- Smoking, LVEF, NT-ProBNP, history of tachyarrhythmia, and treatment with pioglitazone, oral anticoagulants or diuretics
Use of antidiabetic drugs with cardiovascular benefits
- SGLT2i use
- 30.4%
- GLP-1 RA use
- 12.5%
- Despite an average suboptimal glycaemic control
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →